TRIAL DETAIL

Imatinib Mesylate in Treating Patients With Locally Advanced Gastrointestinal Stromal Tumor

Drug:
Trial Name:
Imatinib Mesylate in Treating Patients With Locally Advanced Gastrointestinal Stromal Tumor
NCT#:
Conditions:
Gastrointestinal Stromal Tumor
Status:
Completed
Phase:
2
Start Date 02/01/2005
Age of Trial (yrs) 16.8
Treatment Phase:
Neoadjuvant
Drug Category:
KIT/PDGFRA inhibitor
Strategy:
Block KIT
Trial Type:
Specifically GIST and only GIST
Other Protocol IDs:
CDR0000430499 KRDI-TUM-GIST-SCTI571-BDE43 EU-20507
Sponsor:
Technische Universitat Munchen
Patient Contact:
Contact email:
Contact Phone:
Randomized:
IV or Oral:
Oral
Trial Notes:
This is a neoadjuvant trial of imatinib (Glivec).

Trial Links

Trial Results

Drug Information

All About Gleevec (LRG website)
 
Gleevec prescribing information
 
Patient assistance program (insurance, financial help, etc).
 
Gleevec blood level monitoring (LRG story/info)
 
Gleevec drug interactions (LRG site)
 
Gleevec.com website (GIST portion)
 
FDA approves adjuvant Gleevec
 
Effect of a proton pump inhibitor on the pharmacokinetics of imatinib
 
Imatinib Mesylate May Improve Fasting Blood Glucose in Diabetic Ph+ Chronic Myelogenous Leukemia Patients Responsive to Treatment
 
European Commission approves new label for Novartis drug GlivecĀ® extending adjuvant therapy to three years for certain GIST patients
 
Disintegration of chemotherapy tablets (including imatinib) for oral administration in patients with swallowing difficulties
 
Imatinib-induced hyperbilirubinemia with UGT1A1 (*28) promoter polymorphism: first case series in patients with gastrointestinal stromal tumor.
 

Trial Sites

Name
Address
City
State
Zip
Country
Vienna
A1090
Austria
Weisbaden
D-65199
Germany
Munich
D-81675
Germany
Hamburg
D-20246
Germany
Lindenberger Weg 80
Berlin
D-13125
Germany
Tuebingen
D-72076
Germany
Bonn
D-53105
Germany
Cologne
D-50924
Germany
Munich
D-81377
Germany